Active Biotech AB Interim Report January - September 2011

November 3, 2011 08:30 (CET)
  • Laquinimod - Phase III BRAVO trial concluded. Teva plans an additional clinical study before filing a registration application in the US   
  • TASQ - enrolment of patients for Phase III trial ongoing 
  • TASQ -  Phase II trial published in Journal of Clinical Oncology
  • ANYARA - Phase III trial proceeding according to plan 
  • 57-57 - a clinical trial in  being prepared in systemic sclerosis
  • ISI - project is proceeding as planned
  • RhuDex® - preparations for continued clinical development ongoing
  • Net sales  SEK 231.3 M (8.5)
  • Operating loss SEK 6.2 M (loss: 149.7)  
  • Loss after tax SEK 1.3 M (loss: 156,8)
  • Loss per share for the period amounted to SEK 0,02 (loss: 2.40)  

For further information, please contact:

Tomas Leanderson
President and CEO
Tel +46 (0)46-19 20 95                        

Hans Kolam, CFO                                       
Tel: +46 (0)46-19 20 44                                

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00       
Fax: +46 (0) 46-19 11 00

This report is also available at www.activebiotech.com                

Active Biotech AB Interim Report Jan-Sep 2011